vs
FEDERATED HERMES, INC.（FHI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是FEDERATED HERMES, INC.的1.6倍（$772.1M vs $482.8M），FEDERATED HERMES, INC.净利率更高（22.2% vs 12.7%，领先9.4%），FEDERATED HERMES, INC.同比增速更快（13.7% vs 5.9%），FEDERATED HERMES, INC.自由现金流更多（$294.6M vs $161.8M），过去两年FEDERATED HERMES, INC.的营收复合增速更高（10.4% vs 9.0%）
方德贺明是总部位于美国宾夕法尼亚州匹兹堡的投资管理机构，成立于1955年，1957年10月18日正式注册。截至2025年12月，公司受托管理客户资产规模达9026亿美元，可为客户提供股票、固定收益、另类/私募市场、多资产及流动性管理等多元投资策略，产品覆盖共同基金、ETF、独立账户、封闭式基金和集合投资基金等品类。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FHI vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.6倍
$482.8M
营收增速更快
FHI
高出7.8%
5.9%
净利率更高
FHI
高出9.4%
12.7%
自由现金流更多
FHI
多$132.8M
$161.8M
两年增速更快
FHI
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $482.8M | $772.1M |
| 净利润 | $107.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 28.1% | 14.5% |
| 净利率 | 22.2% | 12.7% |
| 营收同比 | 13.7% | 5.9% |
| 净利润同比 | 26.4% | 3.9% |
| 每股收益（稀释后） | $1.38 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FHIRVTY
| Q4 25 | $482.8M | $772.1M | ||
| Q3 25 | $469.4M | $698.9M | ||
| Q2 25 | $424.8M | $720.3M | ||
| Q1 25 | $423.5M | $664.8M | ||
| Q4 24 | $424.7M | $729.4M | ||
| Q3 24 | $408.5M | $684.0M | ||
| Q2 24 | $402.6M | $691.7M | ||
| Q1 24 | $396.4M | $649.9M |
净利润FHIRVTY
| Q4 25 | $107.0M | $98.4M | ||
| Q3 25 | $104.1M | $46.7M | ||
| Q2 25 | $91.0M | $53.9M | ||
| Q1 25 | $101.1M | $42.2M | ||
| Q4 24 | $84.7M | $94.6M | ||
| Q3 24 | $87.5M | $94.4M | ||
| Q2 24 | $21.0M | $55.4M | ||
| Q1 24 | $75.0M | $26.0M |
毛利率FHIRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率FHIRVTY
| Q4 25 | 28.1% | 14.5% | ||
| Q3 25 | 27.6% | 11.7% | ||
| Q2 25 | 27.6% | 12.6% | ||
| Q1 25 | 31.1% | 10.9% | ||
| Q4 24 | 26.0% | 16.3% | ||
| Q3 24 | 27.4% | 14.3% | ||
| Q2 24 | 10.1% | 12.4% | ||
| Q1 24 | 24.9% | 6.8% |
净利率FHIRVTY
| Q4 25 | 22.2% | 12.7% | ||
| Q3 25 | 22.2% | 6.7% | ||
| Q2 25 | 21.4% | 7.5% | ||
| Q1 25 | 23.9% | 6.4% | ||
| Q4 24 | 19.9% | 13.0% | ||
| Q3 24 | 21.4% | 13.8% | ||
| Q2 24 | 5.2% | 8.0% | ||
| Q1 24 | 18.9% | 4.0% |
每股收益（稀释后）FHIRVTY
| Q4 25 | $1.38 | $0.86 | ||
| Q3 25 | $1.34 | $0.40 | ||
| Q2 25 | $1.16 | $0.46 | ||
| Q1 25 | $1.25 | $0.35 | ||
| Q4 24 | $1.08 | $0.77 | ||
| Q3 24 | $1.06 | $0.77 | ||
| Q2 24 | $0.20 | $0.45 | ||
| Q1 24 | $0.89 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $582.5M | $919.9M |
| 总债务越低越好 | $348.4M | — |
| 股东权益账面价值 | $1.2B | $7.3B |
| 总资产 | $2.2B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.29× | — |
8季度趋势，按日历期对齐
现金及短期投资FHIRVTY
| Q4 25 | $582.5M | $919.9M | ||
| Q3 25 | $506.3M | $931.4M | ||
| Q2 25 | $371.0M | $991.8M | ||
| Q1 25 | $387.6M | $1.1B | ||
| Q4 24 | $504.4M | $1.2B | ||
| Q3 24 | $375.0M | $1.2B | ||
| Q2 24 | $307.4M | $2.0B | ||
| Q1 24 | $359.8M | $1.7B |
总债务FHIRVTY
| Q4 25 | $348.4M | — | ||
| Q3 25 | $348.3M | — | ||
| Q2 25 | $348.2M | — | ||
| Q1 25 | $348.2M | — | ||
| Q4 24 | $348.1M | — | ||
| Q3 24 | $348.0M | — | ||
| Q2 24 | $348.0M | — | ||
| Q1 24 | $347.9M | — |
股东权益FHIRVTY
| Q4 25 | $1.2B | $7.3B | ||
| Q3 25 | $1.2B | $7.4B | ||
| Q2 25 | $1.1B | $7.6B | ||
| Q1 25 | $1.1B | $7.6B | ||
| Q4 24 | $1.1B | $7.7B | ||
| Q3 24 | $1.1B | $7.9B | ||
| Q2 24 | $1.0B | $7.9B | ||
| Q1 24 | $1.1B | $7.8B |
总资产FHIRVTY
| Q4 25 | $2.2B | $12.2B | ||
| Q3 25 | $2.2B | $12.1B | ||
| Q2 25 | $2.2B | $12.4B | ||
| Q1 25 | $2.0B | $12.4B | ||
| Q4 24 | $2.1B | $12.4B | ||
| Q3 24 | $2.0B | $12.8B | ||
| Q2 24 | $1.9B | $13.4B | ||
| Q1 24 | $2.1B | $13.4B |
负债/权益比FHIRVTY
| Q4 25 | 0.29× | — | ||
| Q3 25 | 0.29× | — | ||
| Q2 25 | 0.31× | — | ||
| Q1 25 | 0.32× | — | ||
| Q4 24 | 0.32× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.30× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $297.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $294.6M | $161.8M |
| 自由现金流率自由现金流/营收 | 61.0% | 21.0% |
| 资本支出强度资本支出/营收 | 0.6% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.78× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $427.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流FHIRVTY
| Q4 25 | $297.3M | $182.0M | ||
| Q3 25 | $103.1M | $138.5M | ||
| Q2 25 | $18.8M | $134.3M | ||
| Q1 25 | $14.3M | $128.2M | ||
| Q4 24 | $346.6M | $174.2M | ||
| Q3 24 | $117.1M | $147.9M | ||
| Q2 24 | $88.7M | $158.6M | ||
| Q1 24 | $14.0M | $147.6M |
自由现金流FHIRVTY
| Q4 25 | $294.6M | $161.8M | ||
| Q3 25 | $101.6M | $120.0M | ||
| Q2 25 | $18.0M | $115.5M | ||
| Q1 25 | $13.3M | $112.2M | ||
| Q4 24 | $342.5M | $149.8M | ||
| Q3 24 | $114.1M | $125.6M | ||
| Q2 24 | $82.7M | $136.6M | ||
| Q1 24 | $13.5M | $129.7M |
自由现金流率FHIRVTY
| Q4 25 | 61.0% | 21.0% | ||
| Q3 25 | 21.6% | 17.2% | ||
| Q2 25 | 4.2% | 16.0% | ||
| Q1 25 | 3.1% | 16.9% | ||
| Q4 24 | 80.7% | 20.5% | ||
| Q3 24 | 27.9% | 18.4% | ||
| Q2 24 | 20.5% | 19.7% | ||
| Q1 24 | 3.4% | 20.0% |
资本支出强度FHIRVTY
| Q4 25 | 0.6% | 2.6% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 0.2% | 2.6% | ||
| Q1 25 | 0.2% | 2.4% | ||
| Q4 24 | 0.9% | 3.4% | ||
| Q3 24 | 0.7% | 3.3% | ||
| Q2 24 | 1.5% | 3.2% | ||
| Q1 24 | 0.1% | 2.7% |
现金转化率FHIRVTY
| Q4 25 | 2.78× | 1.85× | ||
| Q3 25 | 0.99× | 2.97× | ||
| Q2 25 | 0.21× | 2.49× | ||
| Q1 25 | 0.14× | 3.03× | ||
| Q4 24 | 4.09× | 1.84× | ||
| Q3 24 | 1.34× | 1.57× | ||
| Q2 24 | 4.22× | 2.87× | ||
| Q1 24 | 0.19× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FHI
| Investment Advisory Management And Administrative Service | $314.0M | 65% |
| Separateaccounts | $63.9M | 13% |
| Other | $61.2M | 13% |
| Distribution Service | $43.7M | 9% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
